- Biotechnology company Allergy Therapeutics reported a slight decline in first-half as an uptick in administrative expenses offset sales growth.

For the six months ended 31 December 2020, pre-tax profit slipped to £15.6 million from £15.9 million year-on-year, while revenue increased by 7% to £54.0 million.

The company's pre-R&D operating profit hit a record of £20.5 million as a result of continued sales growth and operational efficiency.

Administrative expenses climbed to £14.3 million from £9.5 million, owing to investment in compliance and infrastructure.

The company's pre-Investigational new drug meeting with FDA for its VLP peanut programme is scheduled for H1 2021.

At 10:04am: [LON:AGY] Allergy Therapeutics PLC share price was 0p at 13.88p

Story provided by